FedEx Corp. Board Declares Quarterly Dividend

Increases Annual Dividend by 5% After Adjusting for FedEx Freight Spin-Off

MEMPHIS, Tenn.--(BUSINESS WIRE)-- The Board of Directors of FedEx Corp. (NYSE: FDX) today approved a 5% increase in the annual dividend rate on FedEx Corp. common stock, after a one-time annual rate adjustment in connection with the spin-off of FedEx Freight.

The dividend increase and spin-off adjustment result in an annualized dividend rate of $4.88 for the transition period covering June 1, 2026 through Dec. 31, 2026. Consistent with this update, the Board today also declared a quarterly cash dividend of $1.22 per share on FedEx Corp. common stock. The dividend is payable July 7, 2026, to stockholders of record at the close of business on June 22, 2026.

“This dividend increase, coupled with our recent spin-off of FedEx Freight, signals our firm commitment to creating stockholder value,” said Claude F. Russ, FedEx Corp. enterprise vice president and interim CFO. “Our dividend is an important element of our disciplined and multifaceted approach to capital allocation.”

Corporate Overview

FedEx Corp. (NYSE: FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce, and business services. The company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Consistently ranked among the world's most admired and trusted employers, FedEx inspires its employees to remain focused on safety, the highest ethical and professional standards, and the needs of their customers and communities. FedEx is committed to connecting people and possibilities around the world responsibly and resourcefully, with a goal to achieve carbon-neutral operations by 2040. To learn more, please visit fedex.com/about.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260608096544/en/

Media Contact: Caitlin Adams Maier 901-434-8100
Investor Contact: Jeni Hollander 901-818-7200
Home Page: fedex.com

Source: FedEx Corp.

You May Also Be Interested In

• Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
• Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
• Don't Pay Full Price for Power: WattCycle's Prime Day Event Drops Up to 70% Off LiFePO4 Batteries Starting June 15